These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31905677)

  • 1. Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.
    Perotti M; Perez L
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31905677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel vaccines against human cytomegalovirus.
    Cui X; Snapper CM
    Hum Vaccin Immunother; 2019; 15(11):2673-2683. PubMed ID: 31017831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.
    Perotti M; Marcandalli J; Demurtas D; Sallusto F; Perez L
    PLoS Pathog; 2020 Dec; 16(12):e1009169. PubMed ID: 33370407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
    Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
    Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.
    Lehmann C; Falk JJ; Büscher N; Penner I; Zimmermann C; Gogesch P; Sinzger C; Plachter B
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
    Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
    J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
    Gerna G; Lilleri D
    New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
    Schneider-Ohrum K; Cayatte C; Liu Y; Wang Z; Irrinki A; Cataniag F; Nguyen N; Lambert S; Liu H; Aslam S; Duke G; McCarthy MP; McCormick L
    J Virol; 2016 Nov; 90(22):10133-10144. PubMed ID: 27581989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
    Xia L; Su R; An Z; Fu TM; Luo W
    Hum Vaccin Immunother; 2018 Feb; 14(2):292-303. PubMed ID: 29053403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.
    Fu TM; An Z; Wang D
    Vaccine; 2014 May; 32(22):2525-33. PubMed ID: 24681264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
    Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
    J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
    Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
    Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
    Loomis RJ; Lilja AE; Monroe J; Balabanis KA; Brito LA; Palladino G; Franti M; Mandl CW; Barnett SW; Mason PW
    Vaccine; 2013 Jan; 31(6):919-26. PubMed ID: 23246547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
    Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
    J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.